Rob Flavell

The 2025 @AmThyroidAssn management guidelines for adult patients with differentiated thyroid cancer WENT ONLINE TODAY in @thyroidjournal, focusing on the patient journey, personalized/dynamic strategies & evidence! #MedTwitter @clinicalthyroid @ThyCaInc liebertpub.com/doi/10.1177/10…

Plan ahead! The next PSMA conference will be held March 26-27th, 2026. This is the go to conference for learning about clinical use of PSMA radioligand therapies and discussing future directions. It will again be held at the Luskin Center at UCLA.

Had fun collaborating with Ravi Patel (@RPatelMDPHD) & Steve Adler (@IRPatNIH) on this commentary highlighting Rob Flavell's (@flavell_rob) & @anilbidkar1's recent publication showing superior efficacy of alpha #radiopharmaceuticals therapy in micro v macromets 👇

Congrats to @anilbidkar1 on leading this work integrating alpha particle microdosimetry with therapeutic efficacy, and demonstrating the potential of CD46 RPT in the context of disseminated preclinical models.

It's been a while since I posted on some of the ☢️ #radiopharmaceuticals ☢️ work we've been brewing. Let's fix that... 🧵👇 1/5

Exciting news from Flavell Lab(@flavell_rob)! Our latest study on CD46-targeted Actinium-225 alpha particle therapy for disseminated prostate cancer is now online in Clinical Cancer Research. Read it @CCR_AACR: bit.ly/3CYw4Rq #ProstateCancer #Ac225 #CD46 #Theranostics

The 9th Annual PICT Symposium is happening on 3/26! Explore advancements in #Immunotherapy, #Theranostics & #AI in Cancer Imaging, with talks & posters by leading experts & rising researchers. Abstracts due Feb 21, 2025. Register to attend & present: radiology.ucsf.edu/events/9th-ann…

A big victory for patients and the nuclear medicine field! CMS announced the unbundling of diagnostic radiopharmaceuticals at the $630 level, opening access to nuclear medicine scans for patients who need it the most. More here: snmmi.org/Web/News/Artic…

@DrMHofman @PCF_Science @drlouiseemmett @LewisLabMSKCC @RenuEapen @anna_t_g @AzadOncology @declangmurphy @AnnetteVDHeyden @pj_physics @MHaskali @SandhuShahneen Great session!

✨ Wrapping up another incredible @PCF_Science #PCFRetreat24! 🙏It was an honor to organize "New Atoms, New Targets" diving into the future of theranostics with an outstanding lineup of experts. 🔹 @drlouiseemmett what's hot in 2024🔥 🔹 @LewisLabMSKCC new atoms☢️ 🔹 @AarmstrongDuke new targets🚀 🔹 @ButeauJames what's coming in 2025-6 💡Highlights: looking back in history at Dr Saul Hertz' discovery of radio-iodine to see the future of curative theranostics, three new randomised trials published in 2024 (and the year is not finished), so many new targets being explored, the whole period table with PET, SPECT, alpha, beta & Auger emitters waiting to be explored. @soulehoward1 @AndreaMiyahira @pros_tic @PeterMacCC

New in #Theranostics from @UCSFimaging's Drs. Anil Bidkar (@anilbidkar1), Luann Zerefa, Surekha Yadav (@shiningsurekha), Henry VanBrocklin & Robert Flavell (@flavell_rob): "Actinium-225 targeted alpha particle therapy for prostate cancer." thno.org/v14p2969.htm

New @UCSF #LIINC paper: immune activation & viral persistence in tissue up to 2 years post-COVID. Found double-stranded RNA in #LongCOVID, suggesting active reservoir persists and evades immune clearance. Thanks @polybioRF, @NIH for support. @ScienceTM science.org/doi/10.1126/sc…

Breaking!: Research published today in Science Translational Medicine and supported by PolyBio Research Foundation shows that the #SARS-CoV-2 virus can chronically persist in the gut of patients with long COVID for over 2 years: polybio.org/chronic-virus-…

Total-body PET imaging and microscopy analysis of rectosigmoid biopsies reveal prolonged T cell activation and SARS-CoV-2 RNA persistence following COVID-19 science.org/doi/10.1126/sc… @MichaelPelusoMD @Dylan_Ryder1 @flavell_rob

@LewisLabMSKCC @charlesrudin @Tendler_S @morr316 @lisabodei Congratulations! Great work.

So excited, our phase 1/2 first in human imaging w/ [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate, is out. JT Poirier @charlesrudin @LewisLabMSKCC @Tendler_S @morr316 @lisabodei et al., sciencedirect.com/science/articl…

Excited that our new paper is out! Led by Deblin Jana @brownengin @DesaiLabUCSF in collaboration with @flavell_rob @UCSFimaging , we show enhanced prostate specific membrane antigen targeting by DNA scaffolded nanoparticle ligand presentation @acsnano pubs.acs.org/doi/full/10.10…

Happy to share our latest work of the PET/RANO group: link.springer.com/article/10.100… Was exciting to prepare this guideline with so many world experts in the field! @UKKoeln @fz_juelich #btsm #NeuroOncology #PETImaging #Neuroimaging #Meningioma

Incidental hot lesions on prostate-specific membrane antigen (PSMA) PET. Should we be working them up? #RadAdv @RSNA @OUPMedicine @UCSFimaging doi.org/10.1093/radadv…

@NataliaHerAlv @SNM_MI @LewisLabMSKCC Great presentation!

It was an honor to present our work on 225Ac-Radiopharmaceutical Therapy for CD38-targeted Theranostics in a preclinical model of Multiple Myeloma at the @SNM_MI Thanks to the organizers and the very engaged audience! #SNMMI24 @LewisLabMSKCC #MSKCC

🔬 Exciting insights at the 2024 @PSMAconference! Watch Robert Flavell @UCSF delve into PSMA pharmacology & its pivotal role in #ProstateCancer mgmt. Learn how PSMA PET revolutionizes diagnosis & guides therapy for metastatic cases > bit.ly/3OAbMQH #2024PSMAConference

At the #2024PSMAConference, @flavell_rob discussed the promise of antibody-based radiopharmaceuticals for prostate cancer, highlighting their high specificity and addressing challenges like long half-lives. #WatchNow on UroToday > bit.ly/4aRdsha @PSMAconference